Evigrade

Menaquinone-7

Fat-soluble vitamin K2 (MK-7 form)

ATC code: B02BA01(Phytomenadione (vitamin K1))

Brand names – supplements: MenaQ7Supplements are not tested in clinical trials and are not registered as medications.

Updated · Methodology

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

D

Anti-aging and longevity

Not recommended

Menaquinone-7 (MK-7) is a form of vitamin K2 marketed as a supplement to slow aging and extend lifespan. So far no convincing benefit for this use has been shown – there is no evidence base for anti-aging or longevity. Lifespan and age-related changes respond more reliably to sleep, physical activity, diet and not smoking; if you have a vitamin K deficiency, talk to a doctor about supplementation. Important: vitamin K reduces the effect of warfarin and other vitamin K antagonists; patients on these anticoagulants, including those with a mechanical heart valve, must not take vitamin K supplements without medical agreement.

D

Arterial calcification prevention

Not recommended

MK-7 is marketed as protection against arterial calcification. The idea comes from the Rotterdam Study (J Nutr 2004), an observational analysis of 4807 people showing higher dietary K2 intake associated with less aortic calcification. That is a correlation, not proof. The 2024 Cochrane review could not assess direct cardiovascular endpoints because of the lack of well-powered RCTs. Proven cardiovascular prevention rests on blood pressure control, statins, smoking cessation and physical activity. If MK-7 was offered as a substitute for those measures, consider seeking a second opinion. Important: vitamin K reduces the effect of warfarin and other vitamin K antagonists; patients on these anticoagulants, including those with a mechanical heart valve, must not take vitamin K supplements without medical agreement.

How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

Menaquinone-7 (MK-7) is a long-chain form of vitamin K2 with 7 isoprenyl units. Unlike K1 (phylloquinone), MK-7 has a half-life of about 72 hours and maintains stable plasma levels after a single dose. In the liver it acts as a cofactor of gamma-glutamyl carboxylase and activates clotting factors II, VII, IX, X. Extrahepatically it activates osteocalcin (driving calcium incorporation into bone) and matrix Gla-protein (binding calcium in the vessel wall). This second function underpins K2 marketing as a bone and vascular protector.

Safety

Contraindications

  • Vitamin K antagonist therapy (warfarin, acenocoumarol) without INR monitoring
  • Hypersensitivity to menaquinone or excipients

Serious adverse effects

  • Reduced effect of warfarin and other vitamin K antagonists with thrombosis risk
  • Anaphylactoid reactions with parenteral administration (not reported for oral MK-7)

Common adverse effects

  • Mild gastrointestinal discomfort
  • Nausea
  • Skin rash (rare)

Pregnancy: can you take Menaquinone-7?

Controlled MK-7 data in pregnancy are absent. Vitamin K2 is not prohibited in gestation at dietary physiological doses, but additional 90–180 mcg MK-7/day capsules have no proven benefit. AESAN classifies it as a food supplement without therapeutic indication recognised by AEMPS.

Breastfeeding: can you take Menaquinone-7?

Compatible at physiological doses. Hale L3 for supplemental MK-7. Vitamin K transfers poorly into milk: newborns receive a prophylactic K1 injection at birth regardless of maternal intake. MK-7 capsules in the nursing mother do not replace neonatal prophylaxis.

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Menaquinone-7 used for?

Menaquinone-7 is evaluated for the following indications with varying evidence strength: Arterial calcification prevention (evidence tier D), Anti-aging and longevity (evidence tier D). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Menaquinone-7?

Common side effects of Menaquinone-7 (≥ 1 in 100): Mild gastrointestinal discomfort, Nausea, Skin rash (rare). See the Safety section for uncommon and serious reactions.

Is Menaquinone-7 safe during pregnancy?

Controlled MK-7 data in pregnancy are absent. Vitamin K2 is not prohibited in gestation at dietary physiological doses, but additional 90–180 mcg MK-7/day capsules have no proven benefit. AESAN classifies it as a food supplement without therapeutic indication recognised by AEMPS.

Is Menaquinone-7 compatible with breastfeeding?

Compatible at physiological doses. Hale L3 for supplemental MK-7. Vitamin K transfers poorly into milk: newborns receive a prophylactic K1 injection at birth regardless of maternal intake. MK-7 capsules in the nursing mother do not replace neonatal prophylaxis.

Who should not take Menaquinone-7?

Menaquinone-7 is contraindicated in: Vitamin K antagonist therapy (warfarin, acenocoumarol) without INR monitoring; Hypersensitivity to menaquinone or excipients. Full list in the Safety section.

Other drugs in this group

Eltrombopag, Menaquinone (vitamin K2), Phytomenadione, Tranexamic acid